Patients with a favourable decline in human chorionic gonadotropin and alfa-fetoprotein continued BEP ( Fav-BEP group ) for 3 additonal cycles , whereas patients with an unfavourable decline were randomly assigned ( 1:1 ) to receive either BEP ( Unfav-BEP group ) or a dose-dense regimen ( Unfav-dose-dense group ) , consisting of intravenous paclitaxel ( 175 mg/m ( 2 ) over 3 h on day 1 ) before BEP plus intravenous oxaliplatin ( 130 mg/m ( 2 ) over 3 h on day 10 ; two cycles ) , followed by intravenous cisplatin ( 100 mg/m ( 2 ) over 2 h on day 1 ) , intravenous ifosfamide ( 2 g/m ( 2 ) over 3 h on days 10 , 12 , and 14 ) , plus mesna ( 500 mg/m ( 2 ) at 0 , 3 , 7 and 11 h ) , and bleomycin ( 25 units per day , by continuous infusion for 5 days on days 10-14 ; two cycles ) , with granulocyte-colony stimulating factor ( lenograstim ) support .